Consultancy Services for Population Health Programme
Estimated value
£44k
Awarded value
£44k
Awarded 10 Aug 2022
Suppliers
1
Lots
1
1 awarded
Published
29 Nov 2022
Deadline 09 Aug 2022
Other contracts from Midlands & Lancashire C S U· 10
Most recent notices published by the same contracting authority.
| Title | Type | Value | Published |
|---|---|---|---|
| Seymour John - Consultancy contract | contract | £27k | 15 May 2024 |
| Project Consultancy | contract | £12k | 13 May 2024 |
| PharmOutcomes license | call off | £19k | 10 May 2024 |
| contract | £115k | 10 May 2024 | |
| Development, Support and mobilisation of the Senior Operational Leaders Network | contract | £40k | 10 May 2024 |
| Tableau Licences | contract | £95k | 10 May 2024 |
| Digital Project Consultancy | contract | £57k | 10 May 2024 |
| Midlands and Lancashire CSU Supplier Accreditation Scheme - Window 9 | contract | — | 09 May 2024 |
| HII Research Analysis and Evaluation - Inequalities in the Workforce | call off | £59k | 08 May 2024 |
| InterWorks Curator licences and services | contract | £44k | 08 May 2024 |
Other contracts awarded to Costello Medical Consulting Limited· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Health Economics Feasibility Study- Specialised Commissioning | contract | £24k | 17 Oct 2023 |
| C149851_DHSC: OHID: Anorectal malformations Evidence Map | contract | £17k | 24 Mar 2023 |
| DHSC: OHID: Metachromatic Leukodystrophy (MLD) Evidence Map | contract | £16k | 20 Mar 2023 |
| Evidence Map on Screening for Cytomegalovirus | contract | £50k | 18 Jun 2021 |
| PHE - Corporate - Evidence Map on Biotinidase Deficiency | contract | £6k | 09 Jun 2021 |
| PHE - Corporate - Asymptomatic Bacteriuria Screening in Pregnancy | contract | £81k | 26 May 2021 |
| PHE - Corporate - Evidence Map on Neuronal Ceroid Lipofuscinosis Type 2 | contract | £11k | 21 Apr 2021 |
| PHE - Corporate - Screening for Duchenne Muscular Dystrophy | contract | £15k | 31 Mar 2021 |
| PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major | contract | £81k | 03 Nov 2020 |
| PHE - Corporate - Ultrasound Screening for Fetal Presentation at 36 Weeks | contract | £11k | 02 Sept 2020 |